would for Thanks line everybody. quarterly $X.XX present billion. We free to we in $X.XX EBITDA a billion. $X.XX which in. of GAAP morning, $X.XX you; and that seen cash non-GAAP of flow diluted was EPS Good calling expectations. we had Kevin. loss you, The like a billion, was revenues $X.XX Thank results per and to nice with have non-GAAP our we of saw of We diluted saw share very
we the optimization the course new initiated what effect that last long some of X.X American business. North generics by are a saw portfolio supported ongoing of launches It's basically we and of years quarter, ago. stable seeing a also And list we
of good $XX XX% first trend. also strong We very the the up continuous quarter see in the a million AUSTEDO, having and very, continuing second sales quarter, growth of over
We on are now are launches right Share in the TRx we with are AJOVY about happy we undertaking very Europe. that satisfied the and
by spend restructuring our plan, plans, in And we XXXX. reduction we the of completely a the target reduction On course, billion for small debt. gross achieve this And can goes, debt the see of which to a a scheduled reduction with billion the base down guidance. means net our $X are line see, guidance And quarter two-year did reaffirming will the and that a compared of this also XXXX just paying we in reduction see basically $X.X for all financial of your make in information, July. we as you we elements
a see revenue which also is yearly the fall roughly but the the stabilizes. If now on I've trough, we down like remind see, the development we of what of and $X.X it, that's quarterly coming going basically competition calling as $X late to some you where in you 'XX of see coming billion, generic trough the revenues I go to of we to to basis from the also on were historical the $X.X that basically revenue profitability, you ' saw joined COPAXONE I'd in billion when you XX knew beginning and billion just and been revenue situation where
of was long-term is now that that see now, target. our course XX% also above and the down coming also margin XX% just around stabilizing stabilizing is the operating gross You margin which not
XX%. get I'll Our back target, to, as is long-term
So let's the look profit. the at trough, about there. Talking operating we to need still see improvements
very the income the the effect now see now same per in also the cost only that in around $XXX see the revenues still effect stabilizing net being but you big able is operating at we stabilizing If million we around the take and that quarter-by-quarter, to period, are $X.XX. you share profit down of that at look course is us and declining historical now roughly quarter. results per of billion right the around the that $X earnings right then And
everybody, coming we before, this the going start lines slowly operating to in see will profit not trend earnings will remind be be just as share. dramatic is, also there average this EPS terms forward. per in the moderate will years, a increases that to trough Now in lowest on be to I've moderate and and year. will increase turnaround year change But and expect year of this said in is revenues of we It's what terms the a the but
people span. So time just you massive more bit a divesting in or organization very very, this is is of closing world. factories undertaking. whole color base give reduction, the XX,XXX around This to some reducing by a short little a on spend the XX is than This the
everything So according say happy is undertaking that I'm to a plan. executed and being to major
And less as actual in math equivalent $XX.X XXXX. the we billion, billion, this $XX.X our and this the we the $X know, in $X.X that simple spend than billion, is basically which of is you is that spent billion yearly which had target, a first the half means base spend is
includes there. so course tricks there And of is nothing excluded this any everything, or
the that it's So can executing see really to is we nice plan. according a everybody and development
launch of the of launches TRx the we have Europe. in in above have two drivers and US still we've if XX% happy future on started just we and We have the drivers, Now, share growth, we main we AJOVY to AJOVY. about and AUSTEDO had very move strong are
in scripts, the and share. couple we we course waiting that of our that are injector for and launch see an do pay being also pharmacy NBRx in down stopped therefore we a some level auto of patients on the we've We've the it's eagerly think and scripts factors, the moderate where means at the the that AJOVY. declined covered, get old a auto decline to fact cases, the do seen approval related We own not injector prefer which one some of are actually full
we to the we covered of the numbers strong the we see in terms If net then, sales, course very growth AUSTEDO plans is and the always think of very, marketplace. to all see is continue both also very much of situation gross health by prescriptions stable. that It's there AUSTEDO here quarterly terms a in reflection But very are and of turn situation well true we of in variances. some to basically
So this is really exciting for us.
dyskinesia. now the more little have on chorea a patient to right and the X,XXX a you it's in combination is If equivalent script think we and about here than patients Huntington's drug numbers of tardive the
before, as And there is the are our around tardive people said that in XXX,XXX US suffering I've estimates dyskinesia. from
the are very So therapy among scratching we with for among have in that very, see surface can the and good reception only you this moment we sense, specialists and patients.
our been linear on next which if the nothing drag really volume There to less go is development a is we you COPAXONE. business, has slide, decline, the stable. more new had or pretty in we can And The see here.
we have and the down quarters rebate have Of means bit so rebates, rebating order course maintain in volume. and go to quarterly up of some this to accruals, course here, variations can a over increased we that because due have and a time we And various again, volume and decline that's that on.
yearly year. you a But the could that the sort are on the having basis also of we business half are underlying at of for say trend, of really this a you that's what if look value we expecting then losing of this, and
are slide, the can have here relative the that We a a have in situation but course, So about we which you of still Europe US we are see a year. our Europe. revenue of we business now this in numbers, expecting which around optimistic $XXX so And million moderate maintaining with to this in European on a more COPAXONE then don't with show we in Patent stable win solid had decline. Office,
say is the extent price and elements have that -- everything significant on Now, interesting with operational capitalization of some it to the all the seen track course share frustrating the in well, I market performing of drop Company. would and being a we
being and involved having a for personally, strong compliance believing a and that all business having commitment compliance to a very many legacy pharmaceutical in at the in all be elements legal levels maybe me is prerequisite for is annoying And industry successful of in to years situations. it business the especially two
that. are situations, the always we you opioid and Company, involved act assess in in interest course, involved in As the our best litigation do these what price-fixing. allocations we of is investigations upon on We in of of and we know, all shareholders are an
-- have, course, discovery documents extensive We external firms. research with of together law done
evidence not or misconduct in have we that because evidence the any we us of all any misconduct area. having have any the our with far, pricing any liability, situation opioid we deny so -- And in price hands, seen in the
So not patients will do think more as solved which going to which continue We we see not a situation ourselves that that need tragic US, opioid systemic we change, a defend we is the litigation. be forward. for will situation, do is to for way the in see situation and there the a situation that very by improve is
collaborate On investigation. DOJ the criminal with of do we in their course the pricing,
the found in our that allegations. any XXXX, I have We them substantiates said been with we collaborating since have and of as not process, documentation sort discovery
continue defend denying ourselves to we So allegations. these
business then Now business if targets the like forward, at look going repeat for forward I'd we our just going the these. financial and to
but as to I've our operating everybody have element about key before, We is margin. plan them what the knows just one said and that is improve talked the in so long-term beginning,
on element good the selling, have make that lot development. cost strong the you're sure by margin happens that the product you that a gross and margin you course manufacturing you Now, optimize of a One sell, you the of optimize overall products your is products you elements. portfolio, and of
want we I XX% the right at the and of level you we are As to XX%. level earlier, showed that improve of up to now
we have simple quite probably of on to net math reducing is our debt keep having need we're of reduce is now, earnings that, right a plan we long-term per and in quarter. debt. because to cash The to cash $XXX order The the million our simple, some course earnings
of just roughly billion $X that's - a year, $X.X XX% that around That's billion.
to cash you the So are guiding $X on billion see, flow. as billion $X.X we also
consistent getting result. at level, to on aiming the most really we're a where generate that we, basis, So of
balance there fluctuations always with ours. With cash, as be a quarterly will big sheet
that are yearly important basis, of quarterly on to cash fluctuations. earnings. target a it's there course Of very we meet this But XX% the
And reduce need the important we to debt. that because is
know, we is that do debt. get generate now is and X. our net the you As below and really way ratio cash X want it back to only to And about debt-to-EBITDA right the pay
down way debt. we to stated pay will as that's we we the outstanding use do we really I've to times, our all plan not shareholders. And use also cash to think raise cash the to And continue best debt. plan So value continue to our create for long-term equity, to flows reduce many to
these financials in Now the financial like with will who detail. it to Mike, through targets, turn over go I'd to
